The cost-effectiveness of using resultsbased financing to reduce maternal and perinatal mortality in Malawi by Chinkhumba, Jobiba Joe Henderson et al.
 1Chinkhumba J, et al. BMJ Global Health 2020;5:e002260. doi:10.1136/bmjgh-2019-002260
The cost- effectiveness of using results- 
based financing to reduce maternal and 
perinatal mortality in Malawi
Jobiba Chinkhumba   ,1,2 Manuela De Allegri,3 Stephan Brenner,3 
Adamson Muula,4 Bjarne Robberstad2
Original research
To cite: Chinkhumba J, 
De Allegri M, Brenner S, 
et al. The cost- effectiveness 
of using results- based 
financing to reduce maternal 
and perinatal mortality in 
Malawi. BMJ Global Health 
2020;5:e002260. doi:10.1136/
bmjgh-2019-002260
Handling editor Lei Si
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjgh- 2019- 002260).
Received 27 December 2019
Revised 13 March 2020
Accepted 15 April 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Jobiba Chinkhumba;  
 jchinkhumba@ mac. medcol. mw
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
AbsTrACT
Introduction Results- based financing (RBF) is being 
promoted to increase coverage and quality of maternal and 
perinatal healthcare in sub- Saharan Africa (SSA) countries. 
Evidence on the cost- effectiveness of RBF is limited. We 
assessed the cost- effectiveness within the context of an 
RBF intervention, including performance- based financing 
and conditional cash transfers, in rural Malawi.
Methods We used a decision tree model to estimate 
expected costs and effects of RBF compared with status 
quo care during single pregnancy episodes. RBF effects 
on maternal case fatality rates were modelled based on 
data from a maternal and perinatal programme evaluation 
in Zambia and Uganda. We obtained complementary 
epidemiological information from the published literature. 
Service utilisation rates for normal and complicated 
deliveries and associated costs of care were based on the 
RBF intervention in Malawi. Costs were estimated from 
a societal perspective. We estimated incremental cost- 
effectiveness ratios per disability adjusted life year (DALY) 
averted, death averted and life- year gained (LYG) and 
conducted sensitivity analyses to how robust results were 
to variations in key model parameters.
results Relative to status quo, RBF implied incremental 
costs of US$1122, US$26 220 and US$987 per additional 
DALY averted, death averted and LYG, respectively. The 
share of non- RBF facilities that provide quality care, life 
expectancy of mothers at time of delivery and the share 
of births in non- RBF facilities strongly influenced cost- 
effectiveness values. At a willingness to pay of US$1485 (3 
times Malawi gross domestic product per capita) per DALY 
averted, RBF has a 77% probability of being cost- effective.
Conclusions At high thresholds of wiliness- to- pay, RBF is 
a cost- effective intervention to improve quality of maternal 
and perinatal healthcare and outcomes, compared with the 
non- RBF based approach. More RBF cost- effectiveness 
analyses are needed in the SSA region to complement 
the few published studies and narrow the uncertainties 
surrounding cost- effectiveness estimates.
InTroduCTIon
Identification of policies and strategies that 
can increase coverage of pregnant women 
and newborns with priority maternal and 
newborn health (MNH) services is one of 
the main challenges on the global health 
agenda.1 Although sufficient evidence exists 
on MNH interventions that are effective and 
appropriate for implementation, population 
coverage remains suboptimal in low- income 
and middle- income countries (LMICs), 
especially among the poor.2 Consequently, 
for 2015 in sub- Saharan Africa (SSA) alone, 
1 million babies were stillborn,2 approxi-
mately 0.8 million newborns died within 7 
days of birth,3 4 while 201 000 women died 
from pregnancy- related complications.5 The 
majority of these deaths could have been 
prevented by improved coverage of mothers 
and newborns with existing effective MNH 
interventions.1 6
The SSA region has the highest maternal 
mortality ratio (546 per 100 000 live births) 
and perinatal mortality rate (56 per 1000 
births) in the world.7 8 In order to increase 
population coverage, to narrow disparities 
Key questions
What is already known?
 ► There is increasing evidence that results- based fi-
nancing (RBF) can promote service use and quality 
of maternal and neonatal care.
 ► Little evidence exists ascertaining whether RBF in-
terventions provide value for money in low- income 
and middle- income countries.
What are the new findings?
 ► Introduction of RBF with some infrastructural sup-
port is likely to cost about US$1122 per disability 
adjusted life year averted.
What do the new findings imply?
 ► At high thresholds of willingness to pay, RBF is likely 
to be a cost- effective intervention to promote mater-
nal and neonatal health in Malawi.
 ► More evaluations are merited to explore cost- 
effectiveness of different RBF schemes and to 
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box 1 results- based financing core performance 
indicators
 ► Number of facility- based deliveries.
 ► Number of referrals due to complications at the time of delivery.
 ► Maternal and newborn deaths properly audited according to na-
tional guidelines.
 ► Pregnant women who arrive at the facility for delivery with un-
known HIV status who are tested and treated for PMTCT.
 ► Accurately and completely filled HMIS reports submitted on time to 
the district health office.
 ► Up to date and complete stock cards of essential MNH medicines 
and commodities on the date of verification.
 ► Accurate and complete RBF Initiative specific reports submitted to 
district health offices on time.
HMIS, health management information system; MNH, maternal neonatal 
health; PMTCT, prevention of mother to child transmission; RBF, results- based 
financing.
between income groups and to reduce maternal and peri-
natal mortality, many countries in the region are investing 
in innovative strategies to enhance health system perfor-
mance.9 Strategies such as results- based financing (RBF), 
including both performance- based financing (PBF) and 
conditional cash transfers (CCTs), are currently being 
rolled out.10
RBF consists of monetary or non- monetary transfers 
made to national or subnational governments, managers, 
providers or consumers of health services contingent on 
verified attainment of predefined results.11 Within the 
context of MNH, RBF encompasses both supply and 
demand side mechanisms. On the supply side, PBF is 
designed to act by motivating providers to increase quan-
tity and quality of provided care.12 On the demand side, 
CCTs are designed to lower financial barriers to access 
and modify consumers’ behaviours.13
There is growing evidence that under favourable condi-
tions, RBF schemes can increase service use and quality 
of MNH care in the SSA region.14–16 However, little infor-
mation exists on cost- effectiveness of RBF schemes,17 18 
even though the assessment of the comparative efficiency 
of RBF schemes has been identified as a priority research 
area.19–21 Costing studies have reported high RBF oper-
ational costs raising doubts about the cost- effectiveness 
of these interventions.22 Given limited resources, RBF 
schemes compete for scarce funds with alternative strate-
gies within the healthcare sector. It is therefore essential 
to assess their value for money. Cost- effectiveness infor-
mation on RBF is important to support policy makers 
when making healthcare priority setting decisions.23 24
The objective of this study was to contribute towards 
filling this knowledge gap by assessing the cost- 
effectiveness of an RBF scheme compared with status 
quo care in reducing maternal and perinatal mortality. 
This study was conducted within the framework of a 
larger impact evaluation related to the implementation 
of Results Based Financing for Maternal and Neonatal 
Health (RBF4MNH) Initiative in Malawi.25
MeTHods
study setting
Malawi is 1 of 30 countries in SSA implementing RBF.26 In 
2013, the Malawi Ministry of Health (MoH), with finan-
cial support from the Norwegian Ministry of Foreign 
Affairs and the German Federal Ministry for Economic 
Cooperation and Development, initiated a 5- year RBF 
programme designed to improve coverage and quality 
of MNH services. Selection of facilities was based on 
capacity to offer emergency obstetric care (EmOC), make 
referrals and provide 24/7 delivery care in four districts: 
Balaka, Dedza, Mchinji and Ntcheu. Performance indi-
cators focused on delivery care,27 Box 1. Implementation 
started in 18 out of a total of 33 EmOC facilities in April 
2013 to October 2014 and then expanded to 28 facilities 
until 2017.28
Maternal and neonatal care
MNH care in Malawi is provided at EmOC facilities and 
includes antenatal, delivery and postnatal care. Basic 
EmOC (BEmOC) facilities are expected to consistently 
provide a set of seven key interventions known as ‘signal 
functions’, while two additional signal functions are to 
be provided by Comprehensive EmOC (CEmOC) facil-
ities.29 Health centres providing BEmOC are supposed 
to be capable of managing obstetric complications and 
to refer emergency cases requiring more comprehen-
sive care to CEmOC facilities. MNH and EmOC services 
are provided free in public health facilities and private 
not for profit facilities contracted by the MoH through 
Service Level Agreements.
The intervention
The Malawi RBF Initiative, designed and implemented 
by the MoH, aimed to improve service quality of EmOC 
facilities using performance- based payments to health 
facilities and providers based on achievements of prede-
fined quantity and quality targets (box 1), implying that 
RBF facilities had additional funding on top of central-
ised allocations (budgets, supplies). The RBF Initiative 
also used CCT to incentivise pregnant women to deliver 
at EmOC facilities instead of non- EmOC facilities or at 
home. To ensure that the providers at EmOC facilities 
operated within environments with the required capacity 
to provide quality MNH care, the RBF implementation 
was preceded by a one- off investment in infrastructural 
upgrades and equipment supplies. More details of the 
Malawi RBF Initiative are provided elsewhere.25 28
The comparator
In contrast to RBF- supported EmOC facilities, non- RBF 
EmOC facilities (comparator) neither received funding 
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Figure 1 (A) Pathways of maternal events, demonstrating maternal status after delivery. (A) is linked to perinatal outcomes 
for live mothers. (B) is linked to perinatal outcomes for dead mothers as shown in (B). (B) Pathways of perinatal events, 
demonstrating conditional relationships between perinatal outcomes and maternal status after a delivery event. RBF, results- 
based financing.
Analytic overview
We used a decision tree model to calculate the expected 
health effects and expected costs of the RBF4MNH Initi-
ative from a societal perspective.30 The model simulates 
maternal and perinatal outcomes from 28 weeks gesta-
tion until 7 days after delivery. This period is consistent 
with the definition of perinatal outcomes in developing 
settings.31 32 Importantly, it captures the majority of 
maternal deaths, which occur during the third trimester 
and the first week after birth.33 We considered two alter-
natives: the RBF4MNH Initiative and status quo care 
(comparator). We used the model to estimate deaths 
averted, life- years gained (LYG) and disability adjusted 
life years (DALYs) averted from perinatal and maternal 
complications, as well as the additional (incremental) 
costs incurred by the RBF programme. The model was 
populated with information on population coverage with 
facility- based delivery (FD), the incidence of maternal 
complications, cause- specific maternal case fatality rates 
(CFRs), time to seek care for complications and effective 
coverage (parameter details are explained below).
Malawi- specific estimates for life expectancy at birth 
and life expectancy at the mean age of women of repro-
ductive age were used to calculate LYG34 for each peri-
natal and maternal death averted, respectively. Future 
LYG and DALYs were discounted at 3%23 in the baseline 
scenario, while the influence of no discounting of future 
health was explored in sensitivity analysis.
Each alternative was simultaneously fitted with asso-
ciated treatment costs, including RBF costs for the 
intervention arm. The costs are presented in 2013 
US$. We calculated incremental cost- effectiveness 
ratios (ICERs)35 in terms of cost per DALY and death 
averted and per LYG. The ICER is the difference in 
costs between two interventions divided by the differ-
ence in their effects.36 An intervention is considered 
cost- effective if its ICER in US$ per DALY averted is less 
than three times gross domestic product (GDP) per 
capita and considered ‘very cost- effective’ if its ICER is 
less than the per capita GDP.37 Applied to the Malawian 
context, the RBF intervention would be considered 
cost- effective as long as it costs less than US$1485 per 
DALY averted and very cost- effective if it costs less than 
US$495 per DALY averted.38
Finally, deterministic and probabilistic sensitivity anal-
yses were conducted to assess important drivers impacting 
the ICERs and the robustness of the model to variations 
in key parameter and model assumptions.
The decision model
Reflecting the options decision makers face, the decision 
model included two arms: RBF and non- RBF (compar-
ator). Policy makers decided which facilities received 
RBF while mothers decided whether to deliver in an RBF 
health facility, a non- RBF health facility or at home. In 
the model, mothers’ decisions/service use parameters 
were based on primary trial data. Mothers who delivered 
in RBF facilities benefited from the intervention (combi-
nation of PBF+CCT) while those who delivered in non- 
RBF facilities only received status quo care.
For each delivery, we accounted for both perinatal and 
maternal deaths. We defined each delivery as normal or 
uncomplicated (not associated with any maternal compli-
cation) or complicated (associated with any maternal 
complication). Maternal complications included direct 
causes (haemorrhage, sepsis, obstruction, eclampsia) 
and/or any indirect causes. Each complication could 
lead to a maternal death or recovery. The model allowed 
for the fact that mothers experiencing normal deliveries 
may die from incidental causes.
Because some maternal complications can negatively 
affect perinatal outcomes, perinatal survival is linked to 
maternal survival.33 39 After a delivery event, the model 
therefore considered perinatal outcomes based on 
mothers’ status, that is, whether the mother was alive or 
dead. The outcome of the newborn (ie, stillbirth, early 
neonatal death, alive) was then assigned conditional on 
the status of their mothers. Figure 1A,B gives an over-
view of the decision model. The full model (available 
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epidemiological data
The Malawi RBF trial25 28 was not designed to collect 
health outcomes data including case fatality or mortality 
rates. This lack of health outcomes data necessitated 
modelling. We therefore obtained epidemiological esti-
mates of perinatal mortality, maternal complications 
and CFRs from the published literature to populate the 
corresponding probabilities in the model, assumed to be 
similar for both arms at baseline.
rbF effects on service use, quality and subsequent mortality 
reductions
At population level, maternal/perinatal survival depends 
on both coverage of pregnant women with FD services 
and timely access to quality obstetric emergency care.40 
An impact evaluation of the RBF4MNH on service use did 
not demonstrate any significant differences in utilisation 
with facility delivery rates of 82.8% and 79.8% between 
RBF and comparison non- RBF facilities, respectively.41 
Furthermore, obstetric care utilisation rates among 
women who developed complications outside health 
facilities were 78% and 75%, respectively.42 However, RBF 
was associated with significantly reduced mean time to 
care for women experiencing complications,42 which may 
translate into better survival. Importantly, the RBF impact 
evaluation detected significant improvements in effective 
coverage (ie, provision of higher quality care in respect to 
structural and process quality indicators, such as routine 
use of partographs, uterotonics for active management of 
third stage of labour and infection control).28 41
Similar efforts to improve the quality of obstetric care 
were associated with 25%–30% reductions in CFRs and 
19%–20% reductions in stillbirth rates in Zambia and 
Uganda.43 Given similarity in MNH settings across these 
countries,44 we adopted the mean figures of 27.5% and 
19.5% reductions in CFRs and stillbirth rates with RBF, 
respectively. Consistent with the Zambia and Uganda 
studies, we assumed that RBF had no significant effect 
on early neonatal mortality. Details of parameters used in 
the model and their sources are shown in table 1.
Incidence of maternal complications
Information on incidence of maternal complications 
and respective CFRs is needed to calculate maternal 
deaths. There is wide variation in reported incidences of 
maternal complications even though countries by prin-
ciple adhere to the same version of the International 
Classification of Diseases.45 A WHO multicountry survey 
estimated that 7.3% of FDs in developing countries are 
associated with maternal complications.46 This is prob-
ably the most representative estimate; thus, we used it for 
the baseline scenario. For home births, we assumed that 
the percentage of complicated deliveries was 50% higher, 
given that most home deliveries are not assisted by skilled 
birth attendants in developing countries.47
There is lack of reliable data on case- specific inci-
dences for sepsis, haemorrhage, eclampsia and obstruc-
tion.48 49 However, data on relative frequencies of these 
conditions among women with complications exist. In 
Malawi’s rural facilities, sepsis, haemorrhage, eclampsia 
and obstruction account for 32%, 32%, 20% and 11% of 
obstetric complications, respectively, while other direct/
indirect causes account for the remaining 5%50 (table 1). 
We thus estimated cause- specific incidences indirectly, by 
multiplying the relative frequency of each condition with 
the overall incidence of maternal complications. Overall 
incidence of other direct/indirect causes was estimated 
in a similar way.
Maternal mortality
Regarding maternal CFRs, wide variations exist in data for 
the SSA region. A review of recent estimates (year 2000 
onwards)49 reported that facility based CFRs range from 
3.6% to 18.0% for sepsis;51 52 2.8% to 12.3% for haemor-
rhage;52 53 3.4% to 18.0% for eclampsia51 52 and 2.0% to 
12.7% for obstruction.51 54 We used the mean estimates as 
baseline estimates of CFR and tested the whole ranges in 
sensitivity analyses to reflect this diversity of CFRs across 
SSA settings. As no corresponding data exist for women 
experiencing indirect complications and among home 
births, we adopted the mean CFR (0.09%) to identify 
deaths due to complications from other/indirect causes 
and during home births (table 1).
Though rare, women can have comorbidities or expe-
rience more than one complication, raising the problem 
of competing mortality risks.55 The model applies cause- 
specific incidences concurrently, on the assumption that 
the risk of each maternal complication is independent 
from the risk of other complications. Mortality risk for 
non- maternal causes was approximated by subtracting 
annualised life time risk for maternal death (0.0008) for 
women of reproductive age (15–49 years)56 from annu-
alised all- cause mortality risk (0.0048) for women aged 
25–29 years.34
Perinatal mortality
We calculated perinatal deaths by combining the risk 
of stillbirth and early neonatal mortality with informa-
tion about the status (live or dead) of the mother after 
delivery. The international literature estimates stillbirth 
and early neonatal mortality rates at 28.4/1000 births and 
19.3/1000 live births, respectively, among a population- 
based cohort of mothers that survive births in LMIC.39 
For mothers that die soon after births, the estimated still-
birth and neonatal mortality rates are 318.8/1000 births 
and 89.9/1000 live births, respectively.39 As perinatal 
mortality risks following incidental maternal deaths are 
not linked to maternal complications, we assumed they 
are the same as for normal deliveries. We transformed 
these rates into corresponding probabilities57 (table 1).
Adjusting perinatal risks by place of delivery
Individual studies in SSA report mixed results on risk of 
perinatal mortality by place of delivery; some studies find 
that the risk is lower for FDs58–60 while others report lower 
risks for non- facility based deliveries.61 62 We based our 
by copyright.
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Table 1 List of parameters used in results based financing compared with non- results based financing decision tree model.
Variable name Baseline estimates PSA distributions Sources
Life years gained (discounted)
  Maternal years 25.0%±20%* Normal 34
  Perinatal years 27.8 (22.1–30.5) Normal 34
Outcome probabilities
  Stillbirth if mother is alive 0.028 (0.018–0.038) 39
  Stillbirth if mother is dead 0.273 (0.245–0.301) 39
  Early neonatal death if mother is alive 0.019 (0.011–0.027) 39
  Early neonatal death if mother is dead 0.086 (0.069–0.103) 39
  Maternal death from incidental causes 0.004±20%* 34 56
Maternal complications (%)
  Facility- based births 7.31 (0.07–0.08) 46
  Home- based births 10.9%±20%* Assumption
  Maternal case fatality rates (%)
  Sepsis 10.8 (3.6–18.0) 52 89
  Haemorrhage 7.6 (2.8–12.3) 52 53
  Obstruction 7.4 (2.0–12.7) 54 89
  Eclampsia 10.7 (3.4–18.0) 52 89
  Other/complicated home births 9.1%±20%* Assumption
Share of complications (%)
  Sepsis 32.0 (27.3–36.7) 50
  Haemorrhage 32.0 (27.3–36.7) 50
  Obstruction 11.0 (7.8–14.2) 50
  Eclampsia 20.0 (16.0–24.0) 50
  Others 5.0 (2.8–7.2) 50
Disability weights
  Sepsis 0.133 (0.088–0.190) 66
  Haemorrhage 0.324 (0.220–0.442) 66
  Obstruction 0.324 (0.220–0.442) 66
  Eclampsia 0.260%±20%*
  Others 0.133 (0.088–0.190)
Service use (%)
  Births in RBF facilities 82.8 (80.8–84.8) Beta 41
  Births in non- RBF facilities 79.8 (76.0–83.6) Beta 41
  Complication care seeking RBF facilities 69.7 (66.0–73.1) 42
  Complication care seeking non- RBF facilities 67.1 (60.2–73.4) Beta 42
  Effective coverage RBF facilities 76.4 (74.2–78.6) Beta 41
  Effective coverage non- RBF facilities 69.1 (64.8–73.4) Beta 41
Effective coverage/quality effects (%)
  Reduction in maternal CFRs 27.5%±20%* 43
  Reduction in stillbirth rate 19.5%±20%* 43
  Reduction in early neonatal death rate 0 43
Relative risks
Stillbirth risk in facilities with vs without effective coverage
  if mother dead 0.8292%±20%* 39 43
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Variable name Baseline estimates PSA distributions Sources
  Perinatal death, home vs facility births 1.2579%±20%* LogNormal 63
Patient costs (US$)
  Normal birth RBF facility 2.72%±20%* 90
  Normal birth, non- RBF facility 2.72%±20%* 90
  Complicated birth, non- RBF facility 13.68%±20%* 42
  Complicated birth, RBF facility 15.15%±20%* 42
  Home delivery 2.00%±20%* Assumption
RBF costs (US$)
  RBF facility 36 016.60±20%* Gamma Estimations
  Non- RBF facility 14 090.49±20%* Estimations
  Incentive woman delivering at RBF facility 5181.00±20%* Estimations
  Incentive health worker† 12 577.01±20%* Estimation
*Sensitivity range based on assumption.
†Precludes incentive money given to health facilities.
PSA, probability sensitivity analysis.
Table 1 Continued
perinatal risk adjustment on a meta- analysis that pooled 
results from population- based cohort studies in SSA.63 
The study reported an OR of 1.21 in perinatal deaths for 
non- facility based compared with facility- based births. 
This was transformed into corresponding relative risk.64
disability adjusted life years estimation
DALYs are the sum of years of life lost (YLL) due to 
premature mortality and the years lived with a disability 
(YLD),65 DALY=YLL + YLD. Maternal YLL were estimated 
as the number of maternal deaths multiplied by the life 
expectancy at 25 years using Malawi life tables.34 Similarly, 
perinatal YLL were estimated as the product of perinatal 
deaths and the life expectancy at birth. Maternal YLD 
were estimated by multiplying prevalence of maternal 
complications by their corresponding disability weights65 
(table 1). Since disability weights for eclampsia and other 
maternal conditions are not available,66 we adopted 
the mean disability weight of haemorrhage, sepsis and 
obstruction (0.260) for eclampsia and 0.133 for other 
maternal conditions66 assuming that most of them would 
be related to infections given the high infectious disease 
prevalence in the SSA region.67 Perinatal YLD were not 
estimated due to lack of data.
Cost data
We collected health systems and RBF4MNH programme 
costs from four health centres. We randomly selected 
two districts, and within each district, randomly selected 
an intervention and a comparison health centre. From 
these, we collected cost data twice, in 2014 and in 2015, 
to cover two separate fiscal years. Given some differences 
in actual timing of RBF implementation between inter-
vention health centres, the periods of data collection 
were not identical.
We used the World Bank RBF toolkit to guide 
cost data collection.68 We defined costs as variable 
(changing with service volume) or fixed (not changing 
with service volume). For variable costs, we used an 
ingredient approach to estimate unit costs.23 At the 
health facilities, we identified and recorded quanti-
ties of resources used for maternal and new- born care. 
We used pharmacy and inventory records to quantify 
drugs and other supplies. Unit prices were obtained 
from Malawi Central Medical Stores catalogue or local 
retailers as appropriate.69 Information on utilities, 
building maintenance were either collected at the 
health facilities or respective district offices, depending 
on where complete records were available. RBF data on 
incentives, training, information and communication 
materials, equipment supplies, upgrades and supervi-
sion were collected from both RBF desk officers at the 
health facility and/or the main RBF office at the MoH 
Reproductive Health Unit. We used the consumer price 
index to convert prices into 2013 constant prices before 
discounting them at 3%.23
For fixed costs (building and equipment), information 
on useful life years and replacements costs was obtained 
from MoH Planning and Policy Directorate and from 
the National Health Accounts.70 We annualised and 
discounted the fixed costs at 3% rate and used a top- down 
approach to allocate joint or shared costs using allocation 
proxies.23 For instance, we used the proportion of mater-
nity unit area relative to the area of all hospital units to 
allocate building costs to the maternity unit, while we 
used the share of maternity unit clients among all visits to 
allocate health worker salaries. An implicit assumption of 
the latter is that resource requirements of the maternity 
unit are equal to the average resource requirement of all 
facility activities.
We used facility registers and human resource records 
to find information on births, staffing levels and cadres. 
Costs related to administrative support from the district 
by copyright.
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Table 2 Facility characteristics and provider economic 
costs (US$)
RBF Non- RBF
Number of sampled facilities 2 2
Catchment area population/facility 23 494 41 124
Number of deliveries/facility/years 1212 1506
Number of health workers per facility 30 26
Qualified professionals (eg, nurses) per 
facility
5 4
Fixed costs per year/facility
Building rentals 2861 2700
Office furniture 240 232
Salaries 9339 6281
MoH provided medical equipment 1977 1367
RBF renovations/maternal shelters 8894
RBF provided medical equipment 2306
RBF training and capacity building 2454
Subtotal fixed costs 28 071 10 579
Variable costs per year/facility
Supplies 1027 579
Drugs 1914 1571




RBF health worker incentives 12 577
RBF woman incentives 5181
Subtotal variable costs 25 703 3511
Grand total 53 774 14 090
Mean cost per delivery 44,37 9,36
IEC, information, education and communication; MoH, Ministry of 
Health; RBF, results- based financing.
offices were not collected, on the assumption that they 
would not substantially differ between health centres. 
We estimated RBF personnel costs, office rentals and 
other overhead costs from the central office by inflating 
all RBF costs by 38.8%. In this way, the overall RBF 
administrative costs account for 28% of total imple-
mentation costs, which is consistent with a pay for 
performance programme in Tanzania.22 Household 
costs, including direct and indirect costs, associated 
with care seeking were based on our earlier analyses.42 
Local currency values were converted to US$ equiva-
lents using the 2013 midyear exchange rate (US$1=MK 
330).
sensitivity analyses and parameter uncertainty
We first explored the impact of each model parameter on 
ICERs through one- way sensitivity analyses.71 We varied 
the mean of each parameter over appropriate reported 
ranges. We used normal approximation methods to 
estimate ranges for binomial parameters in cases where 
corresponding CIs were not provided.72 In the absence 
of empirical estimates, parameters were varied ±20% 
(table 1). The 10 parameters that influenced the ICERs 
most were further assessed through probabilistic sensi-
tivity analyses after assignment of appropriate distri-
butions. Gamma distributions were specified for costs, 
normal distribution for LYG, lognormal distributions 
for probabilities and Beta distributions for service use.30 
Bounds for the parameters were derived using methods 
of moments.30 We conducted parametric bootstrapping 
based on 5000 iterations to propagate parameter uncer-
tainty through the model and presented the results as 
cost–effectiveness scatter plot and acceptability curves. 
At any given value of willingness to pay, acceptability 
curves show the probability of an intervention being cost- 
effective relative to the comparator.
Model validation
We validated the model by comparing baseline perinatal 
mortality rates with estimates from the published litera-
ture (internal validity) and by inspecting that all parame-
ters influence the model according to expectations (face 
validity).
Patient and public involvement
It was not appropriate or possible to involve patients or 
the public in the design, or conduct, or reporting, or 
dissemination plans of our research.
resulTs
Costs of rbF
The estimated economic cost per delivery at an RBF 
facility was US$44 or about five times the cost for a 
comparison non- RBF facility. Most of the extra costs 
were RBF related, driven by new medical equipment 
investments, financial rewards and programme moni-
toring. RBF facilities tended to be larger with higher 
staffing levels. RBF facilities also had higher non- RBF 
related budget lines. A health worker in an RBF facility 
received US$420 annually as individual rewards. This 
amount varied by health worker cadre, with more qual-
ified health workers (eg, nurse- midwives) receiving 
almost three times the reward amount compared with 
lower qualified health staff (eg, community health 
workers). Eligible mothers received US$6 on average 
in CCTs, of which more than 50% was used for reim-
bursing costs directly linked to institutional delivery 
(table 2 and online supplementary table 1).
Cost-effectiveness of rbF relative to non-rbF
The model estimated that RBF would avert one addi-
tional DALY (maternal and perinatal), one additional 
death (maternal and perinatal) and gain one additional 
life year (maternal and perinatal) at an incremental 
cost of US$1122, US$26 220 and US$987, respectively. 
Averted perinatal DALYs, deaths and LYG contributed 
most to the total effects (table 3).
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Costs (US$) Effects Costs (US$) Effects Costs (US$) Effects
DALYs (all) 40.06 1.3770 10.68 1.4032 29.39 0.0261 1122
  Perinatal 1.2901 1.3079 0.0178 1646
  Maternal 0.0868 0.0952 0.0083 3525
Deaths (all) 40.06 0.0499 10.68 0.0510 29.39 0.0011 26 220
  Perinatal 0.0463 0.0470 0.0006 45 841
  Maternal 0.0036 0.0041 0.0005 61 260
LYG (all) 40.06 51.3933 10.68 51.3635 29.39 0.0297 987
  Perinatal 26.5502 26.5324 0.0178 1646
  Maternal 24.8431 24.8312 0.0119 2470
*Estimates using TreeAgePro 2016 software.
DALY, disability adjusted life years (discounted); ICER, incremental cost- effectiveness ratio; LYG, life years gained (discounted); RBF, results- 
based financing.
Figure 2 One- way sensitivity analysis showing variations in incremental cost- effectiveness ratios per disability adjusted life 
year averted. RBF, results- based financing.
one-way sensitivity analysis
The share of non- RBF facilities providing quality care, 
the life expectancy of mothers at time of delivery and 
the share of births in non- RBF facilities had the strongest 
impact on ICERs for any DALY averted (figure 2). Rela-
tive to baseline, increases/decreases in the share of 
non- RBF facilities providing quality care would lead to 
more favourable/unfavourable ICERs while high/low 
life expectancies of mothers at time of delivery would be 
associated with unfavourable/favourable ICERs. The 10 
parameters with most influence on RBF cost- effectiveness 
are shown in figure 2.
Probabilistic sensitivity analyses
The ICER scatter plot illustrates that all iterations of 
DALYs for RBF relative to non- RBF consistently have 
positive costs, reflecting higher RBF costs with certainty. 
However, some have less (negative) DALYs relative to non- 
RBF, reflecting that the probability of overall lower health 
effects in the RBF arm relative to non- RBF cannot be 
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Figure 3 (A) Incremental cost- effectiveness scatter plot for RBF relative to non- RBF. (B) Cost- effectiveness acceptability 
curves for RBF compared with non- RBF funding option. RBF, results- based financing.
completely ruled out (figure 3A). The probabilities that 
RBF is cost- effective compared with non- RBF at different 
levels of willingness to pay are shown in figure 3B. At a 
willingness to pay of US$495, US$990 and US$1485, (1X, 
2X and 3X Malawi GDP per capita, respectively), RBF has 
a 0%, 35% and 77% probability of being cost- effective. 
At a willingness to pay of US$1144 per DALY averted, 
RBF and non- RBF have equal probabilities of being cost- 
effective. Thus, with a lower willingness to pay for health 
(<US$1144), non- RBF is most likely to be optimal, while 
at higher levels of willingness to pay RBF represents the 
more optimal policy.
When deaths averted (maternal and perinatal) are 
used as a measure of health benefit, the threshold is at a 
willingness to pay of US$26 500 per death averted. For a 
lower willingness to pay, non- RBF remains optimal, while 
RBF is the policy choice with highest probability of being 
optimal when the willingness to pay for a life is higher 
than this threshold (online supplementary figure 1).
Model validation
The model structure was informed by data availability 
and consensus view that it reasonably represents the 
situation on the ground. It estimates perinatal mortality 
rate of 47/1000 births in the baseline scenario, which is 
comparable to 56/1000 live births reported for the SSA 
region8 and 40/1000 live births estimate for Malawi.73
dIsCussIon
This study demonstrates that an RBF intervention with a 
strong quality improvement component is probably cost- 
effective compared with status quo care. These results 
were produced in a context characterised by high levels 
of FDs and in the absence of significant changes in service 
use. Most of the health benefits resulted from averted 
perinatal deaths due to improvements in quality of care, 
underscoring the potential gains for newborn survival if 
RBF is rolled out.
This is the first full economic evaluation of an RBF 
(combining PBF and CCT components) intervention 
for MNH in a low- income country. We therefore have no 
relevant previous studies against which our results may 
be compared. When maternal or perinatal outcomes 
are considered separately, our ICER results are larger 
compared with findings by Alfonso et al17 for a voucher 
programme in Uganda, which reported an ICER per 
maternal death averted of US$20 756, which is 1/3 of the 
US$61 260 per maternal death averted in this study. This 
estimate however ignores the benefits in terms of peri-
natal health. Our ICER results are also larger than those 
published by Hounton et al74 assessing a health worker 
surgery training aimed at increasing access to EmOC 
in Burkina Faso, which reported an ICER per perinatal 
death averted of US$11 757. We estimated an ICER of 
US$45 841 per perinatal death averted, although this 
estimate ignores maternal health benefits. In Zambia, 
Zeng et al75 have reported an ICER of US$809 per Quality 
adjusted life year gained for a PBF scheme, but this esti-
mate only considers financial costs. Compared with some 
specific MNH interventions including quality improve-
ments efforts76 and new- born care,77 RBF has higher 
ICERs per DALY averted. However, RBF is a broader and 
more complex intervention, where capturing all effects 
is challenging. We find substantially lower ICERs when 
we combine both maternal and perinatal outcomes, 
confirming assertions that the cost- effectiveness of 
MNH interventions is underestimated if benefits are 
assessed separately, rather than jointly, for mothers and 
perinates.20
Because the RBF4MNH intervention appears more 
effective and also more costly than providing MNH 
care under status quo conditions, decisions to adopt 
it would depend on policy makers’ willingness to pay. 
At a willingness to pay of US$1485 per DALY averted, 
policy makers can be 77% certain that RBF is more cost- 
effective compared with status quo care. This confidence 
is reduced to 50% if we consider a willingness to pay of 
US$1144 and further reduces to 35% at willingness to pay 
of US$990 per DALY averted.
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The choice of a new intervention is not based on 
cost effectiveness analysis (CEA) results alone but 
also on the capacity of resource- constrained govern-
ments to sustain its routine use.78 The implications 
for low- income countries like Malawi, where coverage 
gaps in other vital MNH interventions still remain, is 
that implementing new costly interventions based on 
the WHO threshold can only occur at the expense of 
displacing other interventions, thus risking lowering 
overall population health attainment and increasing 
health inequalities.79 Going forward, an important line 
of inquiry is therefore to conduct a budget impact anal-
ysis of the RBF4MNH. Besides ascertaining the afford-
ability of RBF and potential dividends from economies 
of scale in case of scale up, such analysis may also offer 
needed insight regarding broader impact of RBF on 
other interventions.
Our model is sensitive to estimates of non- RBF facil-
ities with effective coverage and share of births in non- 
RBF facilities (both directly influenced by quality of 
care) and life expectancy of mothers at time of delivery. 
Quality of care is important in RBF programmes and 
there are ongoing efforts to improve its measurement 
and reporting.80 The observed sensitivity underscores the 
importance of quality as it relates to health outcomes and 
that better data are needed to improve our model accu-
racy. The sensitivity to RBF costs is not surprising, given 
the financial outlays associated with RBF.81 It does none-
theless highlight the imperative to contain operational 
costs and improve programme efficiencies. Though the 
model is sensitive to the share of births in both RBF and 
non- RBF facilities, it is not as sensitive to the percentage 
of complications among facility deliveries (FD), which 
depends on FD coverage since women with complication 
self- select into care, especially when FD rates are less than 
40%.82 As FD rates are variable in SSA, ranging from as 
low as 12% in Ethiopia83 to as high as 91% in Malawi,84 we 
postulate that cost- effectiveness of RBF may be strongly 
influenced by the share of obstetric complications at 
much lower FD rates than those obtained in Malawi. In 
this regard, CEA studies in different setting are required 
to contextualise findings.
We did not consider benefits from potential reduc-
tions in perinatal morbidity due to lack of quality data. 
Studies on MNH report a heavier morbidity burden due 
to disabilities than to mortality per se.85 Inclusion of 
averted perinatal morbidity would thus increase effective-
ness and improve cost- effectiveness of RBF. Future CEA 
studies should account for the potential of RBF to reduce 
all disabilities.20
We observed large differences in rewards based on 
cadre. The size of financial rewards is assumed to posi-
tively influence performance86 while perceived unfair-
ness in distribution of rewards may demotivate staff, 
undermining RBF objectives. Assessment of adequacy 
of rewards, perceived fairness in how rewards are shared 
and their impact on health system performance should 
inform future lines of inquiries.87
This study has limitations. First, estimates of RBF 
effects on stillbirths and CFRs were based on programme 
evaluations in Zambia and Uganda due to lack of 
randomised trial data. Intense monitoring and super-
vision under programme settings may have improved 
programme effectiveness, biasing our results downwards. 
We attempted to minimise this by using mean effective-
ness estimates in the baseline scenario. Second, we were 
not able to account for maternal deaths that occurred 
before 28 weeks of gestation due to lack of data. The 
share of maternal deaths before 28 weeks is small and 
as early maternal deaths are not explicitly targeted by 
RBF, they may be assumed to be a constant that does not 
affect our estimation. Thus, we believe that this omission 
is less likely to substantially bias the effectiveness esti-
mates. Third, the model considered diverse events and 
use of incidence in DALY estimation would have been 
more appropriate. We cannot ascertain how use of prev-
alence based approach affected our results but given use 
of similar approach by recent global burden of disease 
estimates,65 we believe our results can be trusted. Fourth, 
RBF was preceded by one- off infrastructural/equipment 
support. Disentangling the effects of such investments 
from the quality effects of RBF is problematic. Our results 
therefore represent the costs and effects of the combi-
nation of infrastructural improvements and RBF rather 
than RBF alone. Fifth, not all central level start- up costs 
were captured. This might have led to underestimating 
RBF costs. We attempted to characterise these uncertain-
ties by using wide ranges (±20%) in probabilistic sensi-
tivity analysis and found that the main results were stable 
across these ranges. Finally, GDP- based thresholds have 
been shown to be easily attainable and unconnected to 
local budget constraints;88 the reader should note this 
caveat when considering our results.
ConClusIon
The RBF4MNH Initiative is a potentially cost- effective way 
to fund health facilities to improve quality of maternal 
and perinatal health, and to increase pregnant women’s 
access to EmOC, compared with the current non- RBF 
based funding in Malawi.
Although delivery services at RBF supported facilities 
are about five times as expensive per delivery compared 
with services offered at non- RBF facilities, we estimate that 
the intervention will avert 1.5% of perinatal and 12.1% of 
maternal deaths that occur with status quo MNH care in 
Malawi. The cost of US$1122 per DALY averted is lower 
than Malawi’s three times GDP per capita, which is one of 
the decision rules towards implementation.
More RBF CEAs are merited to explore cost- 
effectiveness of different intervention types, different 
health systems settings and health services and to reduce 
uncertainties around RBF CEA estimates related to 
modelling. Researchers in SSA should take advantage 
of the numerous RBF studies being implemented in 
the region to generate needed economic information 
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to support policy decisions. Further, RBF studies should 
particularly prioritise generating more health outcomes 
data, while future economic evaluations should focus on 
identifying optimal RBF designs and implementation 
models that have lower transactional costs. This would 
allow to better assess the adequacy of different reward 
options and aspects of fairness in the allocation mech-
anisms to maximise individual health worker and team 
efforts.
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